XASX
NX1
Market cap4mUSD
Mar 12, Last price
0.02AUD
Name
Inhalerx Ltd
Chart & performance
P/E
—
P/S
17.27
EPS
—
Div yield, %
—
Shrs. gr., 5y
21.71%
Rev. gr., 5y
48.37%
Revenues
335k
-72.17%
Net income
-1m
L-11.58%
CFO
-369k
L-81.20%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 2016 and headquartered in Sydney, Australia, InhaleRx Limited is an Australian company primarily engaged in advancing and bringing to market medical drug delivery systems. The firm also dedicates efforts to developing specialized inhaled drug formulations. A notable product within its portfolio is the Medihale inhaler, a distinctive sealed-pod device engineered for compatibility with its inhaled medications. This entity formerly traded as Lifespot Health Ltd, officially adopting the name InhaleRx Limited in October 2021.
Key people
David Mandel
Chairman of the Board · since 2017
Rodney Hannington
Independent Non-Executive Chairman of the Board · since 2018
Stefan Schraps
Chief Executive Officer
Company Secretary · since 2018
Non-Executive Director
Andreas Empl
Non-Executive Director · since 2020
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||